Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
- TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
- The injection formulation of Fycompa received manufacturing and marketing approval on January 18, 2024 and was included in the Japan's National Health Insurance (NHI) Drug Price List today.
- Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
- Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and leading to the launch today.